[Systemic enzyme therapy in chronic glomerulonephritis].
To try polyenzyme drug vobenzim in chronic glomerulonephritis (CGN). 174 CGN patients were randomized into 2 groups. The study group of 39 patients received conventional pathogenetic treatment plus vobenzim (initial dose 18-24, maintenance 12-15 dragees a day). Control group of 135 patients were given only pathogenetic therapy. 67 patients appeared ineligible. 3-6 months after the treatment the response was seen in 61.5% patients of the study and 17.8% patients of the control group. Side effects of vobenzim in CGN treatment were absent. Enzyme therapy with vobenzim in CGN is safe and effective.